shutterstock_1396958150_pavel_kapysh-2
Pavel Kapysh / Shutterstock.com
28 January 2021AmericasMuireann Bolger

FTC hits Amneal, Impax and Endo with antitrust suit

The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
1 September 2016   Dublin-based pharmaceutical company Allerganhas revealed that its subsidiaries, Forest Laboratories and Adamas Pharmaceuticals, have entered into a settlement agreement with Amneal Pharmaceuticals.
Americas
11 July 2018   The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.
Big Pharma
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.

More on this story

Americas
1 September 2016   Dublin-based pharmaceutical company Allerganhas revealed that its subsidiaries, Forest Laboratories and Adamas Pharmaceuticals, have entered into a settlement agreement with Amneal Pharmaceuticals.
Americas
11 July 2018   The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.
Big Pharma
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.

More on this story

Americas
1 September 2016   Dublin-based pharmaceutical company Allerganhas revealed that its subsidiaries, Forest Laboratories and Adamas Pharmaceuticals, have entered into a settlement agreement with Amneal Pharmaceuticals.
Americas
11 July 2018   The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.
Big Pharma
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.